Navigation Links
Biostar Pharmaceuticals, Inc. Announces First Quarter 2010 Financial Results
Date:5/17/2010

,060,000 shares issued and outstanding at March 31, 2010 and December 31, 2009 1,467 3,060 Common stock, $.001 par value, 100,000,000 shares authorized, 25,820,119 and 23,374,799 shares issued and outstanding at March 31, 2010 and December 31, 2009 25,820 23,375 Additional paid-in capital 19,992,542 19,801,366 Statutory reserve 3,119,132 2,860,685 Retained earnings 19,553,544 17,548,676 Accumulated other comprehensive income 679,655 682,709 Total Stockholders' Equity 43,372,160 40,919,871 Total Liabilities and Stockholders' Equity $48,926,823 $47,010,469 BIOSTAR PHARMACEUTICALS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS UNAUDITED Three Months Ended March 31, 2010 2009 Sales, net $12,363,175 $7,447,664 Cost of sales 2,840,426 2,658,807 Gross profit 9,522,749 4,788,857 Operating expenses: Selling and distribution 5,609,561 1,888,182 General and administrative 625,722 591,802 Stock-based compensation 154,490 -- Total operating expenses 6,389,773 2,479,984 Income from operations 3,132,976 2,308,873 Other Income (Expense) Interest income 3,686 310 Other expense (6,131) -- Foreign excha
'/>"/>
SOURCE Biostar Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Biostar Pharmaceuticals, Inc. to Launch Xin Aoxing Oleanolic Acid Capsules in Beijing and Shanghai
2. Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
3. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT
4. Biostar Pharmaceuticals, Inc. Retains HC International, Inc. to Implement Investor Relations Program
5. Biostar Pharmaceuticals, Inc. Reports Continued Revenues and Earnings Growth in First Quarter of 2009
6. Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008
7. Inverness Medical Innovations to Close Cholestech, HemoSense and BioStar Facilities
8. Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
9. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
10. Poniard Pharmaceuticals, Inc. to Present Additional Cancer Treatment Data Found Significant by TapeBeat.Com Investors
11. Lotus Pharmaceuticals, Inc. Appoints OTC Division Head
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 24, 2014 The report ... at 19.7% by 2019. It also provides a carefully ... strategies and challenges for the market. , Full Copy ... the report, the global market for cell expansion will ... future. It expects this growth to be driven by ...
(Date:12/24/2014)... 23, 2014 Vermillion, Inc. (Nasdaq:   ... disease, announced today that investors including Oracle Investment ... LLC and several Vermillion directors have agreed to ... Vermillion,s common stock and warrants to purchase unregistered ... placement.  Under the terms of ...
(Date:12/24/2014)...  Rock Creek Pharmaceuticals, Inc., (NASDAQ: RCPI ... Trial Application (CTA) with the United Kingdom,s ... regulatory approval to initiate clinical trials for the continued ... Contingent on the Company receiving CTA regulatory approval, the ... assess the safety, tolerability and dose escalation of Anatabine ...
(Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... Technologies, Inc. , a developer and provider of medical ... second quarter results Tuesday morning, showing both growth and ... high of $18.8 million, the company took a loss ... owing largely to merger and transition costs after acquiring ...
... Madison, Wis. - Esker Software , a provider ... opening of a new mail house at its U.S. headquarters ... Esker on Demand service. , ,The new mail ... facility in Lyon, France and its strategic partners in the ...
... has been appointed to the board of directors of ... former president of the American Society of Therapeutic Radiation ... radiation oncology. , ,Perez is professor emeritus in ... Radiology, Siteman Cancer Center, Washington University Medical Center. , ...
Cached Biology Technology:Cedara acquisition costs hit Merge Technologies numbers 2
(Date:11/21/2014)... 2014  Earlier this year Donald Spector , ... one of the most prolific inventors in the world, ... from Smartphones to third party agencies. Spector envisioned this ... of the earliest known patents in this area. Now ... military, child care, elder care and hospital applications. This ...
(Date:11/21/2014)... , Nov. 20, 2014   Atmel® Corporation ... microcontroller (MCU) and touch technology solutions, today launched the ... with the widest V cc range from ... accuracy and faster I 2 C bus communication speeds, ... EEPROM memory making them ideal for consumer, industrial, computer, ...
(Date:11/18/2014)... The Parenteral Drug Association (PDA) today confirmed that seven officials ... least seven more will participate in the upcoming 2014 PDA ... Washington D.C. , Dec. 2-4. ... the regulatory agencies in the United States ... to help advance the use of metrics in the regulatory ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... 2005, President George W. Bush and American corn farmers saw ... reduce both American dependence on foreign oil and greenhouse gas ... gallons of renewable fuel be added to the gasoline supply ... and 7.5 billion in 2012. Since then, life cycle ...
... Using the meticulous phenological records of two iconic American naturalists, ... native plants in the eastern United States are flowering as ... climate. The new study is important because it gives ... in response to a warming world. In addition, the work ...
... 16, 2013 EcoHealth Alliance, a nonprofit organization that focuses ... on Ebola virus in fruit bats in the peer reviewed ... the Centers for Disease Control and Prevention (CDC). The ... 276 bats scientists screened in Bangladesh. These results suggest ...
Cached Biology News:Photovoltaics beat biofuels at converting sun's energy to miles driven 2Photovoltaics beat biofuels at converting sun's energy to miles driven 3In the Eastern US, spring flowers keep pace with warming climate 2In the Eastern US, spring flowers keep pace with warming climate 3Recent study suggests bats are reservoir for ebola virus in Bangladesh 2
...
BD Falcon Center-well 60 mm In Vitro Fertilization (IVF) Dish, nonembryotoxic, noncytotoxic, tissue-culture treated polystyrene. (20/sp, 500/ca) Packaging: 20 / sleeve, 500 / case ...
...
BD BioCoat Poly-D-Lysine/Laminin 100 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of poly-D-lysine and laminin....
Biology Products: